Muñoz-Garza FZ, Ríos M, Roé-Crespo E, et al. - In this multicenter, randomized, double-blind, placebo-controlled, phase 2a pilot clinical trial, researchers tested the safety and effectiveness of timolol maleate solution, 0.5%, for the early treatment of infantile hemangioma (IH) in infants younger than 60 days. The sample consisted of patients (n = 69) aged 10 to 60 days with focal or segmental hemangiomas (superficial, deep, mixed, or minimal/arrested growth). No significant differences were found between the use of timolol and placebo for complete or nearly complete IH resolution at 24 weeks. At week 4, the timolol group showed a noticeable improvement in lesion color, and topical timolol was well tolerated. When given during the early proliferative stage, topical timolol seems to be well tolerated in the treatment of early proliferative IH, but it appears to have minimal benefit in the resolution of lesions.